XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B XOMAO 深 滬
等待開盤 06-25 09:30:00 美东时间
25.44
+0.009
+0.04%
華盛通- 最 高25.45
- 今 開25.4401
- 成交量 3919股
- 最 低 25.44
- 昨 收 25.431
- 總市值 4478.71万
- 52周最高 26.40
- 市盈率 靜 --
- 換手率 0.22%
- 52周最低 23.5887
- 委 比 28.53%
- 總股本 176.05万
- 歷史最高 26.40
- 量 比 0.47
- 振 幅 0.04%
- 歷史最低 13.5463
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多XOMA Details Merger Timeline and Preferred Share Redemption
An update from XOMA Royalty Corporation ( ($XOMA) ) is now available. On June 1...
06-13 07:53
XOMA Preferred Shares Series A declares $0.539 dividend
XOMA Preferred Shares Series A (XOMAP) declares $0.539/share quarterly dividend, in line with previous. Forward yield 8.47% Payable July 15; for shareholders of record July 2; ex-div July 2. See XOMAP...
06-13 04:14
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
XOMA Royalty Corporation announced that its Board of Directors has authorized cash dividends for holders of its Series A and Series B Preferred Stock, with dividends of $0.53906 per share for Series A and $0.52344 per depositary share for Series B. The Preferred Stock will be redeemed on July 14, 2026, at $25.00 per share or depositary share. Dividends will be paid on July 15, 2026, to holders of record as of July 2, 2026. The redemption is part ...
06-12 20:05
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals
An announcement from XOMA Royalty Corporation ( ($XOMA) ) is now available. On ...
05-18 22:08
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio appoints Christopher Murphy as CFO and Owen Hughes to its Board, enhancing expertise in finance, business development, and royalty management. Murphy brings extensive experience in corporate strategy and investment banking, while Hughes has over two decades of leadership in royalty management and corporate development. AnaptysBio focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to pr...
05-11 13:15
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
05-09 05:57
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-27 23:24
Suja Life launches IPO roadshow, targets $21–$24 per share
Suja Life (SUJA) on Monday said it has begun the roadshow for its initial public offering of 8,888,889 Class A shares, with a price range of $21 to $24 per share. Of the total shares, 8,688,170 are be...
04-27 19:40
Ligand to buy XOMA Royalty for $39/share
Ligand Pharmaceuticals (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share of common stock in cash, for a total equity value of approximately $739M. The transaction has been unanimou...
04-27 19:32
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), both biotechnology royalty aggregators, today announced that the companies have entered into a definitive
04-27 19:06
